The actions of phloridzin on sodium ion transporters and potential difference in nasal airway epithelium.
| ISRCTN | ISRCTN84503991 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN84503991 |
| Protocol serial number | N0236143719 |
| Sponsor | Department of Health |
| Funders | St George's Healthcare NHS Trust (UK), No External Funding, NHS R&D Support Funding |
- Submission date
- 30/09/2005
- Registration date
- 30/09/2005
- Last edited
- 05/04/2011
- Recruitment status
- Stopped
- Overall study status
- Stopped
- Condition category
- Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Emma Baker
Scientific
Scientific
St George's Hospital
University of London
Cranmer Terrace
Tooting
London
SW17 0RE
United Kingdom
| Phone | +44 (0)20 8725 5383 |
|---|---|
| ebaker@sgul.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | In vivo pharmacological study |
| Secondary study design | Other |
| Scientific title | |
| Study objectives | To determine whether nasal application of phloridzin, a sodium-glucose co-transporter (SGLT-1) inhibitor, alters nasal potential difference demonstrating SGLT-1 function. |
| Ethics approval(s) | Wandsworth REC (UK) |
| Health condition(s) or problem(s) studied | Respiratory: Chronic obstructive pulmonary disease (COPD) |
| Intervention | Nasal potential difference: between the 'sensing' electrode in contact with the nasal epithelium, and the 'reference' electrode, a butterfly needle inserted under the skin of the forearm, is measured. Phloridzin in Ringer's solution will then be additionally perfused onto the nasal epithelium and any further change in nasal PD recorded. On a second visit a repeat of the above protocol will be carried out with phloridzin followed be amiloride. |
| Intervention type | Drug |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | phloridzin |
| Primary outcome measure(s) |
Changes in the measured nasal potential difference with phloridzin |
| Key secondary outcome measure(s) |
No secondary outcome measures |
| Completion date | 01/12/2007 |
| Reason abandoned (if study stopped) | Not a clinical trial |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target sample size at registration | 10 |
| Key inclusion criteria | Healthy, non-smoking volunteers with normal nasal mucosa and random plasma glucose <7mmol/l. |
| Key exclusion criteria | 1. Nasal disease 2. Diabetes mellitus 3. Pregnancy |
| Date of first enrolment | 01/10/2002 |
| Date of final enrolment | 01/12/2007 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
St George's Hospital
London
SW17 0RE
United Kingdom
SW17 0RE
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
